Description

Intravitreous Anti-VEGF Treatment for Prevention of Vision Threatening Diabetic Retinopathy in Eyes at High Risk (Protocol W)

The purpose of this study is to determine the efficacy and safety of intravitreous aflibercept injections versus sham injections (observation) for prevention of PDR or CI-DME in eyes at high risk for development of these complications, and to also compare long-term visual outcomes in eyes that receive anti-VEGF therapy early in the course of disease with those that are observed initially, and treated only if high-risk PDR or CI-DME with vision loss develops.

Contact

Wendy Blacutt wbhinojo@bcm.eduPhone 1: (713) 798-3493
IRB: h-38338

Status

Active

Created

Jan 26, 2017